Union Health gives out annual Bhuptani Awards
A ceremony was held to recognize exceptional health care professionals who demonstrate the best qualities of hospital employees, such as compassion and service.
The award is voted on by employees and patients at Union Health.
This year, Joyce Vines won the nursing award, and Aimee Cottrell won the service award.
Cottrell said, the fact that she was recognized by her peers and patients makes this award personally special.
'It means a lot', Cottrell said. 'I couldn't be who I am without them. I am good at my job because I have amazing co-workers, and I have wonderful patients and wonderful doctors that I work with to make my job easy. I would not be successful without them.'
Cottrell said her family has sacrificed a lot for her to pursue this career, so she is planning to use the money and take them somewhere special.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Craig-Hallum Initiates Coverage of Butterfly (BFLY) With a Buy Rating
Butterfly Network, Inc. (NYSE:BFLY) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Craig-Hallum analyst Chase Knickerbocker has initiated coverage of Butterfly Network, Inc. (NYSE:BFLY) with a Buy rating and a $3 price target, citing the company's disruptive position in the point-of-care ultrasound market. Butterfly's proprietary technology replaces traditional piezoelectric crystal-based ultrasound components with a chip-based semiconductor platform, allowing for a single probe to handle multiple imaging needs. This innovation not only reduces manufacturing complexity and cost, but also enables rapid software-driven improvements that set Butterfly apart from most handheld competitors. A doctor looking at a ultrasound system with a Compass software interface, demonstrating the sophistication of the device. The firm's outlook is underpinned by Butterfly's expanding direct-to-consumer (DTC) reach and a growing number of institutional partnerships, including leading health systems and academic centers. These relationships are expected to drive consistent hardware sales while building recurring revenue from software subscriptions. Butterfly Network's technology also places it at the forefront of healthcare's digital transformation. By combining advanced imaging with real-time data interpretation and cloud-based collaboration tools, the company is integrating AI into clinical workflows to enhance diagnostic speed and accuracy. While we acknowledge the potential of BFLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BFLY and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who were born during or entering their first RSV season. To provide a brief context, ENFLONSIA happens to be a preventive, long-acting monoclonal antibody (mAb) which has been designed to offer direct, rapid, and durable protection through 5 months, a typical RSV season, with the same 105 mg dose irrespective of weight. Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year. A close-up of a person's hand holding a bottle of pharmaceuticals. However, ENFLONSIA should not be administered to infants who have a history of serious hypersensitivity reactions, including anaphylaxis, to any of the components of ENFLONSIA. Merck & Co., Inc. (NYSE:MRK) added that the approval is basis the results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of ENFLONSIA administered to preterm and full-term infants. Furthermore, the focus is to ensure the availability of ENFLONSIA in the US before the upcoming RSV season begins. This is to help in reducing the significant burden of the widespread seasonal infection on families and health care systems. Artisan Partners, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Shares of Merck & Co., Inc. (NYSE:MRK), a health care solutions company, were down 9%. Operating results have been solid, with Q4 earnings beating expectations, but investors were more focused on the continued weak demand in China for Gardasil, a vaccine for human papillomavirus (HPV), and the company's decision to pause vaccine shipments through at least mid-2025 to pare inventories. Though recent Gardasil setbacks have weighed on sentiment, the overarching issue for shareholders remains the success of Merck's late-stage pipeline to replace sales that will be lost when blockbuster oncology drug Keytruda (50% of Q4sales) comes off patent in 2028. As shares sell cheaply at just 10X earnings, Merck seems to be getting little credit from investors for the 60+ programs it has in clinical development, despite having several solid and large new product opportunities. Additionally, the company's strong balance sheet and robust free cash flow provide it multiple options for future partnerships and acquisitions, besides return of capital to shareholders via dividends and share repurchases.' While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo data showing notable progress in gene editing for beta thalassemia and sickle cell disease. According to the study, a single dose of the company's proprietary targeted lipid nanoparticle (tLNP) in non-human primates exceeded the therapeutic threshold by achieving a mean on-target editing level of 58% in the HBG1/2 promoter region of hematopoietic stem cells. Editas' position in the gene editing market is strengthened by the result, enhancing the company's potential to offer a novel treatment for these illnesses with favorable biodistribution and minimal liver targeting. A clinical-stage biotechnology company, Editas Medicine, Inc. (NASDAQ:EDIT) develops gene-editing treatments that use CRISPR technology to modify patients' genomes to treat genetic diseases. Editas distinguishes itself from other major biotech companies that are seeking alternative genomic therapeutics by using an 'in vivo gene editing upregulation strategy.' While we acknowledge the potential of EDIT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
